Rapid CAR-T Production Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Rapid Production of CAR-T Cells

Though CAR-T cell therapy is efficient in cancer treatment, the production process is time-consuming. The classical CAR-T production steps involve T cell isolation from peripheral blood, lentivirus packaging, CAR gene delivery, and in vitro large-scale expansion, which typically needs two weeks for manufacturing. A rapid CAR-T production strategy is urgently needed to reduce the waiting time before graft and the loss of potency during long-term cultivation and differentiation. Creative Biolabs is a well-recognized biotech providing advanced CAR-T products and services for global clients, and now we present rapid CAR-T production service for global clients. The rapid CAR-T cells produced using modified approaches retain stem cell-like features and perform durable antitumor functions.

Fig.1 Timeline of traditional long-term CAR-T cell and rapid CAR-T production. (Ghassemi, et al., 2022)

Rapid CAR-T Production Service at Creative Biolabs

With Creative Biolabs' innovative rapid CAR-T production platform, CAR-T cells are rapidly produced from non-activated, primary T cells within a single day with optimized cell culture conditions and high-titter lentiviral vectors.

Primary T Cell Isolation. (Skorka, et al., 2020)

Primary T Cell Isolation

Isolate mononuclear cell or peripheral blood T cells.
Specialized non-activated primary T cells culture medium.

CAR Structure Design and Construction. (Skorka, et al., 2020)

CAR Structure Design and Construction

CAR lentiviral packaging vector design and construction.
Introducing necessary cytokine fusion proteins to lentiviral vectors.
High-quality pseudovirus particles production.

CAR Lentivirus Transduction. (Creative Biolabs)

CAR Lentivirus Transduction

Special cell culture medium for lentiviral transduction.
Optimized cell culture conditions.
Highly efficient lentivirus diffusion and transduction.

CAR-T Cell Cultivation. (Skorka, et al., 2020)

CAR-T Cell Cultivation

Collect CAR-T cells after lentivirus transduction for 24 hours
Test CAR expression using an immunostaining assay
Flow cytometry-based cell phenotyping.

Antitumor Efficacy Tests. (Kandra, et al., 2022)

Antitumor Efficacy Tests

Animal models based in vivo efficacy tests
CAR-T in vivo growth and persistence.

Comparison of Traditional Long-term Culturing CAR-T and Rapid CAR-T

Items	Long-term Culturing CAR-T	Rapid CAR-T
Original Cell	Primary T cell	Primary T cell
Activation	CD3/CD28 Antibodies	None
Lentivirus Transduction Time Points	At dividing stage, after activation for 1-3 days.	At non-dividing stage, direct transduction after isolation.
Lentivirus Transduction Efficiency	High	Low, can be enhanced by various strategies
Expansion Period	6-9 Days	1 Day
Cell Property	Effector memory T cell	Stem cell-like, memory T cell
Antitumor Efficacy After Engraftment	Variant responses, regression, or relapse.	Control tumor burden, persist for long-period.

Key Features of Our Rapid CAR-T Production Service

Time-Saving
Reducing the manufacturing process and culturing period.
Labor-Saving
Reducing cell activation and ex vivo expansion process.
Material-Saving
Avoid the usage of CD3/CD28 antibodies and reduce long-term culturing-related costs.
Potential Anti-tumor Potency
Less differentiated T cells retaining memory phenotype show greater cytotoxicity.

Creative Biolabs has developed a reliable naive T cell transduction strategy for rapid CAR-T cell production. If you have any problem with CAR-T development, please contact us and discuss your program with our experts.

References

Kandra, Prameela, et al. Utility and drawbacks of chimeric antigen receptor T Cell (CAR-T) therapy in lung cancer. Frontiers in Immunology. 2022, 13: 903562.
Skorka, Katarzyna, et al. The application of CAR-T cells in haematological malignancies. Archivum Immunologiae et Therapiae Experimentalis. 2020, 68: 1-19.
Ghassemi, Saba, et al. Rapid manufacturing of non-activated potent CAR-T cells. Nature biomedical engineering. 2022, 6(2): 118-128.